NASDAQ:VACC - Vaccitech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.67
  • Forecasted Upside: 98.92 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$12.40
▼ -0.8 (-6.06%)

This chart shows the closing price for VACC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaccitech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VACC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VACC

Analyst Price Target is $24.67
▲ +98.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vaccitech in the last 3 months. The average price target is $24.67, with a high forecast of $28.00 and a low forecast of $22.00. The average price target represents a 98.92% upside from the last price of $12.40.

This chart shows the closing price for VACC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Vaccitech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021HC WainwrightReiterated RatingBuy$24.00Low
10/22/2021William BlairReiterated RatingBuyLow
7/7/2021HC WainwrightReiterated RatingBuy$25.00Low
5/25/2021William BlairInitiated CoverageOutperformHigh
5/25/2021Jefferies Financial GroupInitiated CoverageBuy$28.00High
5/25/2021Morgan StanleyInitiated CoverageOverweight$22.00High
5/24/2021HC WainwrightInitiated CoverageBuy$25.00Medium
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Read More

Today's Range

Now: $12.40
Low: $12.30
High: $13.40

50 Day Range

MA: $14.25
Low: $12.40
High: $16.50

52 Week Range

Now: $12.40
Low: $12.25
High: $17.99

Volume

10,402 shs

Average Volume

39,662 shs

Market Capitalization

$432.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaccitech?

The following sell-side analysts have issued research reports on Vaccitech in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, William Blair, and Zacks Investment Research.
View the latest analyst ratings for VACC.

What is the current price target for Vaccitech?

3 Wall Street analysts have set twelve-month price targets for Vaccitech in the last year. Their average twelve-month price target is $24.67, suggesting a possible upside of 98.9%. Jefferies Financial Group Inc. has the highest price target set, predicting VACC will reach $28.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $22.00 for Vaccitech in the next year.
View the latest price targets for VACC.

What is the current consensus analyst rating for Vaccitech?

Vaccitech currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VACC will outperform the market and that investors should add to their positions of Vaccitech.
View the latest ratings for VACC.

How do I contact Vaccitech's investor relations team?

Vaccitech's physical mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company's listed phone number is 44-0-18-6581-8808 and its investor relations email address is [email protected] The official website for Vaccitech is www.vaccitech.co.uk.